Skip to main content
Erschienen in: Pediatric Cardiology 6/2017

23.05.2017 | Original Article

Characteristics of Clinically Diagnosed Pediatric Myocarditis in a Contemporary Multi-Center Cohort

verfasst von: Ryan J. Butts, Gerard J. Boyle, Shriprasad R. Deshpande, Katheryn Gambetta, Kenneth R. Knecht, Carolina A. Prada-Ruiz, Marc E. Richmond, Shawn C. West, Ashwin K. Lal

Erschienen in: Pediatric Cardiology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to describe a contemporary cohort of pediatric patients hospitalized for clinically suspected myocarditis. A retrospective chart review was performed at seven tertiary pediatric hospitals. Electronic medical records were searched between 2008 and 2012 for patients ≤18 years admitted with an ICD-9 code consistent with myocarditis. Patients were excluded if the admitting or consulting cardiologist did not suspect myocarditis during the admission or an alternative diagnosis was determined. One hundred seventy-one patients were discharged or died with a primary diagnosis of myocarditis. Median age was 13.1 years (IQR 2.1, 15.9), with a bimodal distribution; 24% <2 years and 46% between 13 and 18 years. Patients with moderate or severe systolic dysfunction were younger, had higher BNPs at admission, but had lower troponin. Mortality, heart transplantation, and readmission did not differ between patients who received only IVIG, only steroids, IVIG and steroids, and no immunotherapy. Ninety-four patients (55%) were discharged on heart failure medications, 16 were transplanted, and seven died. The presence at the time of admission of gastrointestinal (GI) symptoms (p = 0.01) and lower echo shortening fraction (SF) (p < 0.01) was associated with death/transplant. Within one year 16% had a readmission, one underwent heart transplant, and 39% received heart failure therapy. Pediatric myocarditis has a bimodal age distribution. The use of IVIG and steroids is not associated with mortality/heart transplantation. The presence of GI symptoms and lower echo SF may identify patients at risk for death and/or transplantation during the admission.
Literatur
2.
6.
Zurück zum Zitat Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M, Baker AL, Perez-Atayde AR, Newburger JW (1994) Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 89(1):252–257CrossRefPubMed Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M, Baker AL, Perez-Atayde AR, Newburger JW (1994) Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 89(1):252–257CrossRefPubMed
8.
Zurück zum Zitat FDA (2016) FDA Guidance: Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices FDA (2016) FDA Guidance: Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices
9.
Zurück zum Zitat Brief NI (2015) NEHI Issue Brief: Real World Evidence: A New Era for Health Care Brief NI (2015) NEHI Issue Brief: Real World Evidence: A New Era for Health Care
10.
Zurück zum Zitat Lyden D, Olszewski J, Huber S (1987) Variation in susceptibility of Balb/c mice to coxsackievirus group B type 3-induced myocarditis with age. Cell Immunol 105(2):332–339CrossRefPubMed Lyden D, Olszewski J, Huber S (1987) Variation in susceptibility of Balb/c mice to coxsackievirus group B type 3-induced myocarditis with age. Cell Immunol 105(2):332–339CrossRefPubMed
11.
Zurück zum Zitat Lyden DC, Olszewski J, Feran M, Job LP, Huber SA (1987) Coxsackievirus B-3-induced myocarditis. Effect of sex steroids on viremia and infectivity of cardiocytes. Am J Pathol 126(3):432–438PubMedPubMedCentral Lyden DC, Olszewski J, Feran M, Job LP, Huber SA (1987) Coxsackievirus B-3-induced myocarditis. Effect of sex steroids on viremia and infectivity of cardiocytes. Am J Pathol 126(3):432–438PubMedPubMedCentral
Metadaten
Titel
Characteristics of Clinically Diagnosed Pediatric Myocarditis in a Contemporary Multi-Center Cohort
verfasst von
Ryan J. Butts
Gerard J. Boyle
Shriprasad R. Deshpande
Katheryn Gambetta
Kenneth R. Knecht
Carolina A. Prada-Ruiz
Marc E. Richmond
Shawn C. West
Ashwin K. Lal
Publikationsdatum
23.05.2017
Verlag
Springer US
Erschienen in
Pediatric Cardiology / Ausgabe 6/2017
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-017-1638-1

Weitere Artikel der Ausgabe 6/2017

Pediatric Cardiology 6/2017 Zur Ausgabe

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

PET kann infarktgefährdete Koronararterien entdecken

04.06.2024 Koronare Herzerkrankung Nachrichten

Der Nachweis aktiver Plaques mittels 18F-Natriumfluorid-PET hilft nicht nur, infarktgefährdete Patienten, sondern auch infarktgefährdete Koronararterien zu erkennen. Von einer gezielten Behandlung vulnerabler Plaques ist man trotzdem weit entfernt.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.